All Posts

onychomycosis-market-CAGR-size-share-trends-growth-population-epidemiology-therapy-therapeutics-treatment
Onychomycosis Therapy Market Set to Balloon Up as Emerging Novel Therapies Continue to Adorn the Space

Onychomycosis is the most commonly prevalent nail infection in adults. It is a fungal infection that leads to discoloration and thickening of the nail plate. It is four to seven times more frequent in toenails, where it often involves several nails. It is a progressive disease and may become widely spread to other ...

Find More

follicular-lymphoma-market-size-share-trends-growth-cagr-population-epidemiology-therapy-therapeutics-treatment
Follicular Lymphoma Market Size Anticipates Growth as the Key Companies Explores Novel Therapeutics Assets

Follicular lymphoma, a sub-type of indolent B cell non-Hodgkin lymphoma (NHL), accounts for approximately 20% of the total NHL cases. It is the most frequently diagnosed indolent lymphoma. On average, each year, 15,000 new Follicular lymphoma cases are diagnosed in the US alone. DelveInsight estimated that in 2020 ...

Find More

pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics
FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Find More

Healthcare-Medical-applications-Apps-benefits-disadvantages-types-future-outlook-growth-key-companies
How Healthcare Apps are Adding New Perspectives to the Healthcare Industry?

The mobile app is one of the fine examples of communications systems. The mobile app comes in various forms and formats to meet the various needs of the user. We have moved so much over a short period that it is extremely difficult to imagine a day without using smartphones or tablet PCs and the apps in it. For eve...

Find More

recent-pharma-news-updates-for-adarx-ixaka-novocure-vor-biopharma
ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series ...

Find More

oncology-based-indications
Evaluating the Present and Future Oncology Market Outlook With Valued Research and Analysis

Oncology deals with the diagnosis and treatment of cancer. It is one of the most dynamic segments moving at a rapid pace in terms of research and development activities, diagnostics, and treatment. Oncology encompassed several diseases (or indications). Oncology Based Indications are further classified as Blood can...

Find More

delveinsights-oncology-based-reports
Assessing the Opportunities and Challenges in the Oncology Segment

Oncology is the study of cancer and encompasses the diagnosis and treatment of cancer. The treatment of cancer requires a multidisciplinary approach which includes medications, surgical, and radiation. The type of approach adopted depends upon the stages, age, and the patient’s preference. Cancer encompasses a g...

Find More

iron-deficiency-anemia-market-size-share-trends-companies-cagr-growth-therapy-treatment-therapeutics-pipeline
Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030

Anemia is a serious cause of global health loss with over 80% of the total cases diagnosed in developing countries, according to several studies. Anemia is characterized by reduced quality of red blood cells, diminished hemoglobin levels and even altered morphology of red blood cells. The symptoms of the condition ...

Find More

Intratumoral Cancer Therapy Market
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer

Cancer is a leading cause of global death, accounting for nearly 10 million deaths in 2020.  However, over the past years, the treatment paradigm of Cancer has transformed with several therapies such as chemotherapies, radiation therapies and immunotherapies available to treat cancer. Even then, there exists a...

Find More

pharma-news-updates-for-roche-mayo-clinic-owlstone-transmedics-google
Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indic...

Find More